Major
Market Players of Pharmaceuticals Industry of Bangladesh:
The major 5 players in Pharma industry in Bangladesh in 2013 are
Square, Incepta Pharma, Beximco, Opsonin Pharma, and Renata. The Square Pharma
is gaining 18.7%, Incepta Pharma 9.8%, Beximco Pharma 8.6%, Opsonin Pharma 5.3%
and Renata is gaining 5.0% of total market share. (See appendix 1 & 2).
Major Products of Pharmaceuticals
Industry in Bangladesh:
In Bangladesh Pharmaceutical Industry, the major products are active pharmaceutical ingredients (APIs) products, therapeutic classes’ products and
dosage forms products. Along with regular forms like tablets, capsules and
syrups, high-tech specialized products like HFA inhalers, CFC inhalers,
suppositories, nasal sprays, injectables, IV infusions, etc. These products
have been well accepted by medical physicians, chemists, patients and the
regulatory bodies of all of their importing countries. The packaging and the
presentation of the products of Bangladesh are comparable to any international
standard.
Contribution
in GDP:
There are 15 sectors in Bangladesh; the
large industry sector includes four sub-sectors such as mining and quarrying; manufacturing; construction;
electricity and gas and water supply. Among
these sub-sectors, the contribution of the manufacturing sector is the highest
in GDP.
Pharmaceuticals industry is medium-large
industry in manufacturing sector. Pharmaceuticals industry is one of the most
growing industries in Bangladesh. 97% of local medicine demands are met by
local Pharma companies. Besides meeting the local demand, the Pharma companies
are exporting their products in 79 countries in the globe. They mainly
exports active pharmaceutical ingredients (APIs)
products, therapeutic classes’ products and dosage forms products.
In fiscal year 2012-2013, the contribution of manufacturing
sector to GDP was 29 percent. And, in fiscal year 2013-2014, the contribution
to GDP has been estimated at 29.61 percent (BBS provisional estimate). (See
appendix 3, 4, &5). (Source: Bangladesh Economic Review 2014)
No comments:
Post a Comment